{"id":391420,"date":"2015-04-21T00:00:00","date_gmt":"2015-04-21T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbason0515-biopharma-malignant-melanoma-first-line-unresectable-metastatic-decision-base-us-2015\/"},"modified":"2026-04-18T23:27:57","modified_gmt":"2026-04-18T23:27:57","slug":"dbason0515-biopharma-malignant-melanoma-first-line-unresectable-metastatic-decision-base-us-2015","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbason0515-biopharma-malignant-melanoma-first-line-unresectable-metastatic-decision-base-us-2015\/","title":{"rendered":"Malignant Melanoma (First-Line Unresectable\/Metastatic) | Decision Base | US | 2015"},"content":{"rendered":"<p><em>Will the Emerging Immunotherapies and BRAF\/MEK Inhibitor Combinations Meet Physicians\u2019 and Payers\u2019 Expectations?<\/em><\/p>\n<p>In recent years, several new, high-priced therapies have been approved for use in first-line unresectable\/metastatic malignant melanoma, making this relatively small market more dynamic and competitive. The launch of these agents has significantly altered the treatment algorithm and improved the outlook for patients; nevertheless, our research indicates that significant clinical and commercial opportunity remains for therapies that can further prolong overall survival (OS). Several therapies are in late-stage development for first-line unresectable\/metastatic malignant melanoma, all of which are showing considerable potential for improving efficacy outcomes in this indication.<\/p>\n","protected":false},"template":"","class_list":["post-391420","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-malignant-melanoma","biopharma-geography-us","biopharma-date-717"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391420","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391420\/revisions"}],"predecessor-version":[{"id":394543,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391420\/revisions\/394543"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391420"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}